Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07172204 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

Study acronym: CHANCE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv3
  2. Start date: Aug 15, 2025 to Sep 16, 2025
    • Study description shortened, about 669 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.
Trial Details
NCT Number NCT07172204
Lead Sponsor First Affiliated Hospital of Zhejiang University
Collaborators: AbbVie
Conditions
(from sponsor)		 Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
Related terms Leukemia, Myeloid, Acute
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov